Header cover image

Pre-Market Explosion

DA
DailyInvestorsInvested
Community Contributor

Published

December 17 2024

Updated

December 17 2024

Narratives are currently in beta

Organigram Holdings Inc. has seen some significant developments in the past four months:

✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront. This acquisition is expected to strengthen Organigram's position in the Canadian cannabis market.

✓ Trading Halts and Resumptions: Organigram's stock trading was halted on December 6, 2024, pending news. Trading resumed shortly after, with the company announcing the Motif Labs acquisition.

√Product Launches: Organigram unveiled its innovative "Edison Sonics Gummies," which utilize sonic technology to enhance the cannabis experiene. And with the market subject to swings, and companies not growing in the market but everywhere else. This is a diamond waiting to be found

https://dailyinvestors.wixsite.com/freelancesolutions

How well do narratives help inform your perspective?

Disclaimer

The user DailyInvestors has a position in TSX:OGI. Simply Wall St has no position in any of the companies mentioned. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value
CA$6.7
67.2% undervalued intrinsic discount
DailyInvestors's Fair Value
Future estimation in
PastFuture-200m-100m0100m200m2014201720202023202420262029Revenue CA$210.3mEarnings CA$31.0m
% p.a.
Decrease
Increase
Current revenue growth rate
14.87%
Pharma revenue growth rate
0.57%